Skip to content

TELO - Telomir Pharmaceuticals, Inc. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchT

Telomir Pharmaceuticals, Inc. Common Stock

TELO · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

T

TELOTelomir Pharmaceuticals, Inc. Common Stock

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $2.09
52-wk low: $0.89
Prev close: $1.53
Mkt cap: $80.5M
Beta: -0.24
P/B: 14.8x

Smart money

7 funds hold a position.

Real smart money

Funds holding this stock

7 holders

Combined position$647K

MI
Millennium
Israel Englander · Q1 2026 13F
$168K
position
QR
Qube Research
Q2 2026 13F

Earnings

Earnings

Results versus expectations

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $80M

Valuation

P/B14.76

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: TELO
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $80.47M
Beta: -0.24

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

+0.0%

ROE

-213.1%

$28K

position

CI

Citadel

Ken Griffin · Q2 2026 13F

$17K

position

4 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 4 holders

Coverage gaps for TELO

No recent insider trade
No recent Congress trade
No recent market-voice mention

The latest quarter is still settling.

A verdict appears once the reported figure is final

Next report

What the street expects next

-213.1%

ROA-122.8%

Growth

Beta-0.24